Aprea Therapeutics Appoints Eugene Kennedy, MD, as Chief Medical Advisor to Advance WEE1 Inhibitor Program
ByAinvest
Wednesday, Feb 4, 2026 8:32 am ET1min read
APRE--
Aprea Therapeutics has appointed Eugene Kennedy, MD, as Chief Medical Advisor. Kennedy is a seasoned physician scientist and biopharmaceutical executive with 20 years of experience in oncology clinical development, regulatory strategy, and senior corporate leadership. He will strengthen the Company's clinical leadership as it advances its WEE1-focused DNA damage response program and build on its recent early clinical proof-of-concept. Kennedy has a track record of leading complex oncology programs and supporting data-driven decisions.

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet